v3.26.1
Condensed Consolidated Income Statements (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues $ 61,679 $ 52,182
Costs and operating expenses:    
Cost of revenue, excluding depreciation and amortization 36,064 28,789
Research and development 2,664 2,840
Clinical operations, net 1,874 1,856
Sales and marketing 13,849 13,926
General and administrative 12,818 5,207
Depreciation and amortization 1,537 649
Total costs and operating expenses 68,806 53,267
Loss from operations (7,127) (1,085)
Financial income, net (945) (1,526)
(Loss) income before taxes on income (6,182) 441
Income tax expense 124 123
Net (loss) income $ (6,306) $ 318
Net (loss) income per share:    
Basic $ (0.04) $ 0
Diluted $ (0.04) $ 0
Weighted average shares used to compute net (loss) income per share:    
Basic 167,075,636 168,670,861
Diluted 167,075,636 175,545,887